nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—lung cancer	0.517	1	CbGaD
Raltegravir—UGT1A1—Erlotinib—lung cancer	0.102	0.381	CbGbCtD
Raltegravir—UGT1A1—Irinotecan—lung cancer	0.0923	0.344	CbGbCtD
Raltegravir—UGT1A1—Etoposide—lung cancer	0.0739	0.275	CbGbCtD
Raltegravir—CCR1—respiratory system—lung cancer	0.00181	0.403	CbGeAlD
Raltegravir—CCR1—bone marrow—lung cancer	0.00106	0.236	CbGeAlD
Raltegravir—CCR1—lung—lung cancer	0.000961	0.214	CbGeAlD
Raltegravir—CCR1—lymph node—lung cancer	0.000657	0.146	CbGeAlD
Raltegravir—CCR1—GPCR ligand binding—OXTR—lung cancer	0.000454	0.00778	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GRP—lung cancer	0.000454	0.00778	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.000439	0.00751	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GNG11—lung cancer	0.000425	0.00728	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA3—lung cancer	0.000417	0.00714	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.000416	0.00712	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000405	0.00693	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—lung cancer	0.000384	0.00657	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA4—lung cancer	0.000381	0.00653	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUNB—lung cancer	0.000381	0.00652	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA2—lung cancer	0.000371	0.00636	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—PRDX1—lung cancer	0.000367	0.00628	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GIPR—lung cancer	0.000367	0.00628	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTA1—lung cancer	0.000358	0.00614	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTHLH—lung cancer	0.000355	0.00609	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTM2—lung cancer	0.000345	0.0059	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—ANXA1—lung cancer	0.000334	0.00572	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GIPR—lung cancer	0.000333	0.0057	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000323	0.00554	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—POMC—lung cancer	0.00032	0.00549	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—APP—lung cancer	0.000317	0.00542	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GRM8—lung cancer	0.000312	0.00534	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CNDP2—lung cancer	0.000302	0.00518	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTM2—lung cancer	0.000302	0.00518	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM2—lung cancer	0.000298	0.00511	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—lung cancer	0.000296	0.00506	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—HPGDS—lung cancer	0.000283	0.00485	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GRM8—lung cancer	0.000283	0.00485	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—lung cancer	0.000279	0.00477	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA3—lung cancer	0.000278	0.00476	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTT1—lung cancer	0.000275	0.0047	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP2A7—lung cancer	0.000273	0.00468	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GCLC—lung cancer	0.000272	0.00465	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—POMC—lung cancer	0.00027	0.00463	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP2A7—lung cancer	0.00027	0.00462	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—KEAP1—lung cancer	0.000261	0.00447	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AXL—lung cancer	0.000259	0.00444	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GRP—lung cancer	0.000257	0.0044	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—OXTR—lung cancer	0.000257	0.0044	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA4—lung cancer	0.000254	0.00435	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL8—lung cancer	0.000248	0.00425	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA2—lung cancer	0.000248	0.00424	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—AVP—lung cancer	0.000246	0.00422	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA3—lung cancer	0.000244	0.00417	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTA3—lung cancer	0.00024	0.00412	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GNG11—lung cancer	0.00024	0.00411	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTA1—lung cancer	0.000239	0.00409	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—ABCC3—lung cancer	0.000236	0.00405	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—OXTR—lung cancer	0.000233	0.00399	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GRP—lung cancer	0.000233	0.00399	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA4—lung cancer	0.000223	0.00382	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTA4—lung cancer	0.00022	0.00377	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GNG11—lung cancer	0.000218	0.00374	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA2—lung cancer	0.000217	0.00372	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—ADCY1—lung cancer	0.000216	0.0037	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000215	0.00368	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—NFE2L2—lung cancer	0.000211	0.00361	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTA1—lung cancer	0.00021	0.00359	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL8—lung cancer	0.000209	0.00358	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—COL4A2—lung cancer	0.000202	0.00346	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFA—lung cancer	0.000201	0.00344	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PTHLH—lung cancer	0.000201	0.00344	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—AKR1C1—lung cancer	0.000198	0.00339	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GIPR—lung cancer	0.000197	0.00337	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ADCY1—lung cancer	0.000196	0.00336	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PPP2R1B—lung cancer	0.000191	0.00327	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTP1—lung cancer	0.00019	0.00326	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—ANXA1—lung cancer	0.000189	0.00323	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SDC4—lung cancer	0.000184	0.00314	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTHLH—lung cancer	0.000182	0.00312	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GCLC—lung cancer	0.000181	0.0031	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—CYP2A6—lung cancer	0.000181	0.0031	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—DUSP3—lung cancer	0.00018	0.00308	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—APP—lung cancer	0.000179	0.00307	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RHEB—lung cancer	0.000176	0.00302	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTM1—lung cancer	0.000175	0.003	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ANXA1—lung cancer	0.000171	0.00294	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRM8—lung cancer	0.000167	0.00286	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000166	0.00285	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—HPGDS—lung cancer	0.000166	0.00284	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—POMC—lung cancer	0.000164	0.0028	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—APP—lung cancer	0.000163	0.00278	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SKI—lung cancer	0.000162	0.00277	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTT1—lung cancer	0.000161	0.00275	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP2A6—lung cancer	0.000159	0.00272	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GCLC—lung cancer	0.000159	0.00272	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—lung cancer	0.000154	0.00263	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—NQO1—lung cancer	0.000152	0.00261	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—lung cancer	0.000149	0.00256	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PXN—lung cancer	0.000141	0.00241	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AVP—lung cancer	0.000139	0.00238	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—lung cancer	0.000138	0.00236	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRP—lung cancer	0.000138	0.00236	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKR1C1—lung cancer	0.000138	0.00236	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—OXTR—lung cancer	0.000138	0.00236	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP2E1—lung cancer	0.000135	0.00231	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—lung cancer	0.000134	0.0023	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP2E1—lung cancer	0.000133	0.00228	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GNG11—lung cancer	0.000129	0.00221	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—lung cancer	0.000127	0.00217	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—lung cancer	0.000127	0.00217	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AVP—lung cancer	0.000126	0.00217	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFC—lung cancer	0.000123	0.0021	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—lung cancer	0.000117	0.00201	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—lung cancer	0.000117	0.002	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ADCY1—lung cancer	0.000116	0.00198	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SMARCA4—lung cancer	0.000113	0.00193	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PPP2R1B—lung cancer	0.000113	0.00193	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—lung cancer	0.000111	0.00191	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—lung cancer	0.00011	0.00188	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HSPB1—lung cancer	0.000109	0.00187	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTHLH—lung cancer	0.000108	0.00185	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—lung cancer	0.000102	0.00175	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ANXA1—lung cancer	0.000101	0.00173	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—lung cancer	0.000101	0.00173	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FLT1—lung cancer	9.81e-05	0.00168	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—lung cancer	9.72e-05	0.00166	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP1A1—lung cancer	9.7e-05	0.00166	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APP—lung cancer	9.6e-05	0.00164	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH3—lung cancer	9.6e-05	0.00164	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP1A1—lung cancer	9.57e-05	0.00164	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF9—lung cancer	9.52e-05	0.00163	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—POMC—lung cancer	9.25e-05	0.00158	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JUNB—lung cancer	9.09e-05	0.00156	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—lung cancer	8.83e-05	0.00151	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—lung cancer	8.54e-05	0.00146	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AZIN2—lung cancer	8.53e-05	0.00146	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—COL4A3BP—lung cancer	8.53e-05	0.00146	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—POMC—lung cancer	8.4e-05	0.00144	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STK11—lung cancer	8.26e-05	0.00141	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6R—lung cancer	8.19e-05	0.0014	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FOXO3—lung cancer	7.97e-05	0.00136	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAP2K1—lung cancer	7.81e-05	0.00134	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—lung cancer	7.76e-05	0.00133	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AVP—lung cancer	7.47e-05	0.00128	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—lung cancer	7.45e-05	0.00128	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ATP5H—lung cancer	7.26e-05	0.00124	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—POMC—lung cancer	7.23e-05	0.00124	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IGF1R—lung cancer	7.19e-05	0.00123	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—lung cancer	7.16e-05	0.00123	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HES1—lung cancer	7.06e-05	0.00121	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RAF1—lung cancer	6.93e-05	0.00119	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—lung cancer	6.84e-05	0.00117	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—lung cancer	6.76e-05	0.00116	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—lung cancer	6.5e-05	0.00111	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PLBD1—lung cancer	6.47e-05	0.00111	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ERBB3—lung cancer	6.46e-05	0.00111	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2—lung cancer	6.21e-05	0.00106	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TERT—lung cancer	6.19e-05	0.00106	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGFR1—lung cancer	6.01e-05	0.00103	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIF1A—lung cancer	5.92e-05	0.00101	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HSD17B10—lung cancer	5.92e-05	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APOA1—lung cancer	5.71e-05	0.000978	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KDR—lung cancer	5.66e-05	0.000969	CbGpPWpGaD
Raltegravir—Somnolence—Etoposide—lung cancer	5.53e-05	0.000365	CcSEcCtD
Raltegravir—Cough—Docetaxel—lung cancer	5.53e-05	0.000365	CcSEcCtD
Raltegravir—Hepatobiliary disease—Methotrexate—lung cancer	5.53e-05	0.000365	CcSEcCtD
Raltegravir—Insomnia—Paclitaxel—lung cancer	5.52e-05	0.000364	CcSEcCtD
Raltegravir—Epistaxis—Methotrexate—lung cancer	5.52e-05	0.000364	CcSEcCtD
Raltegravir—Hypersensitivity—Irinotecan—lung cancer	5.51e-05	0.000364	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CKB—lung cancer	5.5e-05	0.000942	CbGpPWpGaD
Raltegravir—Paraesthesia—Paclitaxel—lung cancer	5.48e-05	0.000362	CcSEcCtD
Raltegravir—Hypertension—Docetaxel—lung cancer	5.47e-05	0.000361	CcSEcCtD
Raltegravir—Bronchitis—Doxorubicin—lung cancer	5.46e-05	0.00036	CcSEcCtD
Raltegravir—Somnolence—Paclitaxel—lung cancer	5.43e-05	0.000358	CcSEcCtD
Raltegravir—Decreased appetite—Etoposide—lung cancer	5.41e-05	0.000357	CcSEcCtD
Raltegravir—Myalgia—Docetaxel—lung cancer	5.4e-05	0.000356	CcSEcCtD
Raltegravir—Arthralgia—Docetaxel—lung cancer	5.4e-05	0.000356	CcSEcCtD
Raltegravir—Chest pain—Docetaxel—lung cancer	5.4e-05	0.000356	CcSEcCtD
Raltegravir—Nausea—Vinorelbine—lung cancer	5.39e-05	0.000356	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Etoposide—lung cancer	5.38e-05	0.000355	CcSEcCtD
Raltegravir—Dyspepsia—Paclitaxel—lung cancer	5.37e-05	0.000355	CcSEcCtD
Raltegravir—Body temperature increased—Cisplatin—lung cancer	5.37e-05	0.000354	CcSEcCtD
Raltegravir—Asthenia—Irinotecan—lung cancer	5.37e-05	0.000354	CcSEcCtD
Raltegravir—Fatigue—Etoposide—lung cancer	5.37e-05	0.000354	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	5.36e-05	0.000354	CcSEcCtD
Raltegravir—Pain—Etoposide—lung cancer	5.32e-05	0.000351	CcSEcCtD
Raltegravir—Constipation—Etoposide—lung cancer	5.32e-05	0.000351	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—lung cancer	5.31e-05	0.00035	CcSEcCtD
Raltegravir—Decreased appetite—Paclitaxel—lung cancer	5.31e-05	0.00035	CcSEcCtD
Raltegravir—Dry mouth—Docetaxel—lung cancer	5.28e-05	0.000348	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—lung cancer	5.28e-05	0.000348	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Paclitaxel—lung cancer	5.27e-05	0.000348	CcSEcCtD
Raltegravir—Fatigue—Paclitaxel—lung cancer	5.26e-05	0.000347	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—lung cancer	5.25e-05	0.000346	CcSEcCtD
Raltegravir—Asthenia—Gemcitabine—lung cancer	5.23e-05	0.000345	CcSEcCtD
Raltegravir—Constipation—Paclitaxel—lung cancer	5.22e-05	0.000344	CcSEcCtD
Raltegravir—Pain—Paclitaxel—lung cancer	5.22e-05	0.000344	CcSEcCtD
Raltegravir—Confusional state—Docetaxel—lung cancer	5.22e-05	0.000344	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—lung cancer	5.21e-05	0.000893	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APC—lung cancer	5.21e-05	0.000893	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KIT—lung cancer	5.21e-05	0.000893	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—NRAS—lung cancer	5.21e-05	0.000893	CbGpPWpGaD
Raltegravir—Urinary tract disorder—Methotrexate—lung cancer	5.18e-05	0.000342	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTM2—lung cancer	5.17e-05	0.000886	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CNDP2—lung cancer	5.17e-05	0.000886	CbGpPWpGaD
Raltegravir—Weight increased—Doxorubicin—lung cancer	5.17e-05	0.000341	CcSEcCtD
Raltegravir—Pruritus—Gemcitabine—lung cancer	5.16e-05	0.00034	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EGF—lung cancer	5.15e-05	0.000883	CbGpPWpGaD
Raltegravir—Urethral disorder—Methotrexate—lung cancer	5.15e-05	0.000339	CcSEcCtD
Raltegravir—Infection—Docetaxel—lung cancer	5.14e-05	0.000339	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—lung cancer	5.14e-05	0.000339	CcSEcCtD
Raltegravir—Feeling abnormal—Etoposide—lung cancer	5.13e-05	0.000338	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—lung cancer	5.12e-05	0.000338	CcSEcCtD
Raltegravir—Diarrhoea—Irinotecan—lung cancer	5.12e-05	0.000338	CcSEcCtD
Raltegravir—Gastrointestinal pain—Etoposide—lung cancer	5.09e-05	0.000336	CcSEcCtD
Raltegravir—Nervous system disorder—Docetaxel—lung cancer	5.07e-05	0.000335	CcSEcCtD
Raltegravir—Thrombocytopenia—Docetaxel—lung cancer	5.07e-05	0.000334	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—lung cancer	5.06e-05	0.000334	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—lung cancer	5.06e-05	0.000334	CcSEcCtD
Raltegravir—Visual impairment—Methotrexate—lung cancer	5.06e-05	0.000334	CcSEcCtD
Raltegravir—Feeling abnormal—Paclitaxel—lung cancer	5.03e-05	0.000332	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—MTMR3—lung cancer	5.03e-05	0.000862	CbGpPWpGaD
Raltegravir—Skin disorder—Docetaxel—lung cancer	5.03e-05	0.000332	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—lung cancer	5.02e-05	0.000331	CcSEcCtD
Raltegravir—Hypersensitivity—Cisplatin—lung cancer	5.01e-05	0.00033	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—MAPK3—lung cancer	4.99e-05	0.000855	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Paclitaxel—lung cancer	4.99e-05	0.000329	CcSEcCtD
Raltegravir—Diarrhoea—Gemcitabine—lung cancer	4.99e-05	0.000329	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—lung cancer	4.98e-05	0.000328	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—lung cancer	4.96e-05	0.000327	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—lung cancer	4.96e-05	0.000327	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—POMC—lung cancer	4.96e-05	0.00085	CbGpPWpGaD
Raltegravir—Dizziness—Irinotecan—lung cancer	4.95e-05	0.000327	CcSEcCtD
Raltegravir—Urticaria—Etoposide—lung cancer	4.95e-05	0.000326	CcSEcCtD
Raltegravir—Abdominal pain—Etoposide—lung cancer	4.92e-05	0.000325	CcSEcCtD
Raltegravir—Body temperature increased—Etoposide—lung cancer	4.92e-05	0.000325	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—lung cancer	4.91e-05	0.000324	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PGAM1—lung cancer	4.9e-05	0.00084	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—lung cancer	4.9e-05	0.000839	CbGpPWpGaD
Raltegravir—Tinnitus—Methotrexate—lung cancer	4.89e-05	0.000323	CcSEcCtD
Raltegravir—Asthenia—Cisplatin—lung cancer	4.88e-05	0.000322	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—lung cancer	4.87e-05	0.000321	CcSEcCtD
Raltegravir—Urticaria—Paclitaxel—lung cancer	4.85e-05	0.00032	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL6R—lung cancer	4.84e-05	0.000829	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CREBBP—lung cancer	4.83e-05	0.000828	CbGpPWpGaD
Raltegravir—Haematuria—Doxorubicin—lung cancer	4.83e-05	0.000318	CcSEcCtD
Raltegravir—Abdominal pain—Paclitaxel—lung cancer	4.83e-05	0.000318	CcSEcCtD
Raltegravir—Body temperature increased—Paclitaxel—lung cancer	4.83e-05	0.000318	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—lung cancer	4.79e-05	0.000316	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—lung cancer	4.78e-05	0.000315	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—lung cancer	4.76e-05	0.000314	CcSEcCtD
Raltegravir—Vomiting—Irinotecan—lung cancer	4.76e-05	0.000314	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—EGFR—lung cancer	4.75e-05	0.000813	CbGpPWpGaD
Raltegravir—Immune system disorder—Methotrexate—lung cancer	4.74e-05	0.000313	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—lung cancer	4.73e-05	0.000312	CcSEcCtD
Raltegravir—Rash—Irinotecan—lung cancer	4.72e-05	0.000311	CcSEcCtD
Raltegravir—Dermatitis—Irinotecan—lung cancer	4.71e-05	0.000311	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Docetaxel—lung cancer	4.71e-05	0.000311	CcSEcCtD
Raltegravir—Chills—Methotrexate—lung cancer	4.71e-05	0.000311	CcSEcCtD
Raltegravir—Headache—Irinotecan—lung cancer	4.69e-05	0.000309	CcSEcCtD
Raltegravir—Insomnia—Docetaxel—lung cancer	4.68e-05	0.000309	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP2A7—lung cancer	4.68e-05	0.000801	CbGpPWpGaD
Raltegravir—Diarrhoea—Cisplatin—lung cancer	4.65e-05	0.000307	CcSEcCtD
Raltegravir—Paraesthesia—Docetaxel—lung cancer	4.65e-05	0.000307	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—lung cancer	4.64e-05	0.000306	CcSEcCtD
Raltegravir—Vomiting—Gemcitabine—lung cancer	4.64e-05	0.000306	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MAP2K1—lung cancer	4.61e-05	0.00079	CbGpPWpGaD
Raltegravir—Somnolence—Docetaxel—lung cancer	4.6e-05	0.000303	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—lung cancer	4.6e-05	0.000303	CcSEcCtD
Raltegravir—Rash—Gemcitabine—lung cancer	4.6e-05	0.000303	CcSEcCtD
Raltegravir—Dermatitis—Gemcitabine—lung cancer	4.59e-05	0.000303	CcSEcCtD
Raltegravir—Hypersensitivity—Etoposide—lung cancer	4.59e-05	0.000303	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—lung cancer	4.58e-05	0.000785	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SDC4—lung cancer	4.58e-05	0.000784	CbGpPWpGaD
Raltegravir—Erythema—Methotrexate—lung cancer	4.57e-05	0.000301	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—lung cancer	4.57e-05	0.000301	CcSEcCtD
Raltegravir—Headache—Gemcitabine—lung cancer	4.57e-05	0.000301	CcSEcCtD
Raltegravir—Dyspepsia—Docetaxel—lung cancer	4.55e-05	0.0003	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—lung cancer	4.55e-05	0.0003	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—lung cancer	4.54e-05	0.000777	CbGpPWpGaD
Raltegravir—Hypoaesthesia—Doxorubicin—lung cancer	4.52e-05	0.000298	CcSEcCtD
Raltegravir—Decreased appetite—Docetaxel—lung cancer	4.5e-05	0.000297	CcSEcCtD
Raltegravir—Hypersensitivity—Paclitaxel—lung cancer	4.5e-05	0.000297	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—lung cancer	4.49e-05	0.000296	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—KRAS—lung cancer	4.49e-05	0.000768	CbGpPWpGaD
Raltegravir—Oedema peripheral—Doxorubicin—lung cancer	4.48e-05	0.000295	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—lung cancer	4.47e-05	0.000295	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Docetaxel—lung cancer	4.47e-05	0.000295	CcSEcCtD
Raltegravir—Asthenia—Etoposide—lung cancer	4.47e-05	0.000295	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—lung cancer	4.47e-05	0.000295	CcSEcCtD
Raltegravir—Fatigue—Docetaxel—lung cancer	4.46e-05	0.000294	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—lung cancer	4.46e-05	0.000294	CcSEcCtD
Raltegravir—Nausea—Irinotecan—lung cancer	4.45e-05	0.000293	CcSEcCtD
Raltegravir—Constipation—Docetaxel—lung cancer	4.42e-05	0.000292	CcSEcCtD
Raltegravir—Pain—Docetaxel—lung cancer	4.42e-05	0.000292	CcSEcCtD
Raltegravir—Back pain—Methotrexate—lung cancer	4.42e-05	0.000292	CcSEcCtD
Raltegravir—Pruritus—Etoposide—lung cancer	4.4e-05	0.000291	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—lung cancer	4.38e-05	0.000289	CcSEcCtD
Raltegravir—Asthenia—Paclitaxel—lung cancer	4.38e-05	0.000289	CcSEcCtD
Raltegravir—Nausea—Gemcitabine—lung cancer	4.33e-05	0.000286	CcSEcCtD
Raltegravir—Vomiting—Cisplatin—lung cancer	4.32e-05	0.000285	CcSEcCtD
Raltegravir—Pruritus—Paclitaxel—lung cancer	4.32e-05	0.000285	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—lung cancer	4.3e-05	0.000284	CcSEcCtD
Raltegravir—Rash—Cisplatin—lung cancer	4.28e-05	0.000283	CcSEcCtD
Raltegravir—Dermatitis—Cisplatin—lung cancer	4.28e-05	0.000282	CcSEcCtD
Raltegravir—Feeling abnormal—Docetaxel—lung cancer	4.26e-05	0.000281	CcSEcCtD
Raltegravir—Diarrhoea—Etoposide—lung cancer	4.26e-05	0.000281	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—lung cancer	4.25e-05	0.00028	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—lung cancer	4.24e-05	0.00028	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—lung cancer	4.24e-05	0.00028	CcSEcCtD
Raltegravir—Gastrointestinal pain—Docetaxel—lung cancer	4.23e-05	0.000279	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—lung cancer	4.22e-05	0.000279	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—lung cancer	4.22e-05	0.000278	CcSEcCtD
Raltegravir—Diarrhoea—Paclitaxel—lung cancer	4.18e-05	0.000276	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—RRM1—lung cancer	4.17e-05	0.000714	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA3—lung cancer	4.17e-05	0.000714	CbGpPWpGaD
Raltegravir—Angiopathy—Doxorubicin—lung cancer	4.12e-05	0.000272	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—lung cancer	4.12e-05	0.000706	CbGpPWpGaD
Raltegravir—Malaise—Methotrexate—lung cancer	4.12e-05	0.000272	CcSEcCtD
Raltegravir—Dizziness—Etoposide—lung cancer	4.12e-05	0.000272	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MDM2—lung cancer	4.11e-05	0.000703	CbGpPWpGaD
Raltegravir—Immune system disorder—Doxorubicin—lung cancer	4.11e-05	0.000271	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—lung cancer	4.11e-05	0.000271	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—lung cancer	4.1e-05	0.00027	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—RAF1—lung cancer	4.09e-05	0.000701	CbGpPWpGaD
Raltegravir—Body temperature increased—Docetaxel—lung cancer	4.09e-05	0.00027	CcSEcCtD
Raltegravir—Abdominal pain—Docetaxel—lung cancer	4.09e-05	0.00027	CcSEcCtD
Raltegravir—Chills—Doxorubicin—lung cancer	4.08e-05	0.000269	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ERBB2—lung cancer	4.05e-05	0.000693	CbGpPWpGaD
Raltegravir—Dizziness—Paclitaxel—lung cancer	4.04e-05	0.000266	CcSEcCtD
Raltegravir—Nausea—Cisplatin—lung cancer	4.04e-05	0.000266	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—lung cancer	4.02e-05	0.000265	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MTOR—lung cancer	3.99e-05	0.000684	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—lung cancer	3.99e-05	0.000684	CbGpPWpGaD
Raltegravir—Cough—Methotrexate—lung cancer	3.99e-05	0.000263	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—lung cancer	3.98e-05	0.000263	CcSEcCtD
Raltegravir—Vomiting—Etoposide—lung cancer	3.96e-05	0.000261	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—lung cancer	3.96e-05	0.000261	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—lung cancer	3.96e-05	0.000261	CcSEcCtD
Raltegravir—Rash—Etoposide—lung cancer	3.93e-05	0.000259	CcSEcCtD
Raltegravir—Dermatitis—Etoposide—lung cancer	3.92e-05	0.000259	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—B4GALT5—lung cancer	3.92e-05	0.000671	CbGpPWpGaD
Raltegravir—Headache—Etoposide—lung cancer	3.9e-05	0.000257	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—lung cancer	3.9e-05	0.000257	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—lung cancer	3.89e-05	0.000257	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—lung cancer	3.89e-05	0.000257	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—lung cancer	3.89e-05	0.000257	CcSEcCtD
Raltegravir—Vomiting—Paclitaxel—lung cancer	3.88e-05	0.000256	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—lung cancer	3.87e-05	0.000256	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.86e-05	0.000255	CcSEcCtD
Raltegravir—Rash—Paclitaxel—lung cancer	3.85e-05	0.000254	CcSEcCtD
Raltegravir—Dermatitis—Paclitaxel—lung cancer	3.85e-05	0.000254	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—lung cancer	3.84e-05	0.000254	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—lung cancer	3.84e-05	0.000254	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCL8—lung cancer	3.84e-05	0.000657	CbGpPWpGaD
Raltegravir—Back pain—Doxorubicin—lung cancer	3.83e-05	0.000253	CcSEcCtD
Raltegravir—Headache—Paclitaxel—lung cancer	3.82e-05	0.000252	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—HRAS—lung cancer	3.81e-05	0.000653	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTA4—lung cancer	3.81e-05	0.000653	CbGpPWpGaD
Raltegravir—Hypersensitivity—Docetaxel—lung cancer	3.81e-05	0.000252	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—lung cancer	3.76e-05	0.000248	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTA2—lung cancer	3.71e-05	0.000636	CbGpPWpGaD
Raltegravir—Asthenia—Docetaxel—lung cancer	3.71e-05	0.000245	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—lung cancer	3.71e-05	0.000635	CbGpPWpGaD
Raltegravir—Infection—Methotrexate—lung cancer	3.7e-05	0.000244	CcSEcCtD
Raltegravir—Nausea—Etoposide—lung cancer	3.7e-05	0.000244	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CASP3—lung cancer	3.67e-05	0.000629	CbGpPWpGaD
Raltegravir—Ill-defined disorder—Doxorubicin—lung cancer	3.67e-05	0.000242	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL2—lung cancer	3.67e-05	0.000628	CbGpPWpGaD
Raltegravir—Pruritus—Docetaxel—lung cancer	3.66e-05	0.000242	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—lung cancer	3.66e-05	0.000241	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—lung cancer	3.66e-05	0.000241	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—lung cancer	3.65e-05	0.000241	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL6—lung cancer	3.65e-05	0.000625	CbGpPWpGaD
Raltegravir—Agitation—Doxorubicin—lung cancer	3.64e-05	0.00024	CcSEcCtD
Raltegravir—Nausea—Paclitaxel—lung cancer	3.63e-05	0.000239	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—lung cancer	3.62e-05	0.000239	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—lung cancer	3.61e-05	0.000238	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTA1—lung cancer	3.58e-05	0.000614	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCND1—lung cancer	3.58e-05	0.000613	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JUN—lung cancer	3.57e-05	0.000611	CbGpPWpGaD
Raltegravir—Malaise—Doxorubicin—lung cancer	3.57e-05	0.000235	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—lung cancer	3.55e-05	0.000235	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ABCC3—lung cancer	3.54e-05	0.000607	CbGpPWpGaD
Raltegravir—Diarrhoea—Docetaxel—lung cancer	3.54e-05	0.000234	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—lung cancer	3.5e-05	0.000231	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MMP9—lung cancer	3.47e-05	0.000595	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—lung cancer	3.46e-05	0.000593	CbGpPWpGaD
Raltegravir—Cough—Doxorubicin—lung cancer	3.45e-05	0.000228	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTEN—lung cancer	3.45e-05	0.000591	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKR1C1—lung cancer	3.43e-05	0.000588	CbGpPWpGaD
Raltegravir—Dizziness—Docetaxel—lung cancer	3.42e-05	0.000226	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—lung cancer	3.42e-05	0.000225	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—lung cancer	3.4e-05	0.000224	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—lung cancer	3.37e-05	0.000223	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—lung cancer	3.37e-05	0.000222	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—lung cancer	3.37e-05	0.000222	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—lung cancer	3.37e-05	0.000222	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AKT1—lung cancer	3.37e-05	0.000577	CbGpPWpGaD
Raltegravir—Anxiety—Doxorubicin—lung cancer	3.36e-05	0.000221	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—lung cancer	3.35e-05	0.000221	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.35e-05	0.000221	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—lung cancer	3.33e-05	0.00022	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—lung cancer	3.32e-05	0.000219	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—lung cancer	3.29e-05	0.000217	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EP300—lung cancer	3.29e-05	0.000564	CbGpPWpGaD
Raltegravir—Vomiting—Docetaxel—lung cancer	3.29e-05	0.000217	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—lung cancer	3.28e-05	0.000217	CcSEcCtD
Raltegravir—Rash—Docetaxel—lung cancer	3.26e-05	0.000215	CcSEcCtD
Raltegravir—Dermatitis—Docetaxel—lung cancer	3.26e-05	0.000215	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—lung cancer	3.26e-05	0.000215	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—lung cancer	3.24e-05	0.000214	CcSEcCtD
Raltegravir—Headache—Docetaxel—lung cancer	3.24e-05	0.000214	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—lung cancer	3.22e-05	0.000212	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—lung cancer	3.22e-05	0.000212	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GNG11—lung cancer	3.21e-05	0.00055	CbGpPWpGaD
Raltegravir—Infection—Doxorubicin—lung cancer	3.21e-05	0.000212	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SRC—lung cancer	3.2e-05	0.000548	CbGpPWpGaD
Raltegravir—Pain—Methotrexate—lung cancer	3.19e-05	0.00021	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—lung cancer	3.17e-05	0.000209	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—lung cancer	3.16e-05	0.000209	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—lung cancer	3.14e-05	0.000207	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—lung cancer	3.12e-05	0.000206	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—VEGFA—lung cancer	3.12e-05	0.000534	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT3—lung cancer	3.09e-05	0.000529	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRAS—lung cancer	3.08e-05	0.000527	CbGpPWpGaD
Raltegravir—Nausea—Docetaxel—lung cancer	3.07e-05	0.000203	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—lung cancer	3.07e-05	0.000203	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ALDOA—lung cancer	3.06e-05	0.000524	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Methotrexate—lung cancer	3.05e-05	0.000201	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NCOA3—lung cancer	2.97e-05	0.000509	CbGpPWpGaD
Raltegravir—Urticaria—Methotrexate—lung cancer	2.96e-05	0.000195	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MAPK3—lung cancer	2.95e-05	0.000505	CbGpPWpGaD
Raltegravir—Body temperature increased—Methotrexate—lung cancer	2.95e-05	0.000194	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—lung cancer	2.95e-05	0.000194	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.94e-05	0.000194	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—lung cancer	2.92e-05	0.000193	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—lung cancer	2.9e-05	0.000191	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ADCY1—lung cancer	2.89e-05	0.000495	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCG2—lung cancer	2.89e-05	0.000495	CbGpPWpGaD
Raltegravir—Somnolence—Doxorubicin—lung cancer	2.87e-05	0.000189	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MYC—lung cancer	2.87e-05	0.000491	CbGpPWpGaD
Raltegravir—Dyspepsia—Doxorubicin—lung cancer	2.84e-05	0.000188	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ENO2—lung cancer	2.83e-05	0.000485	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HPGDS—lung cancer	2.83e-05	0.000485	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPP2R1B—lung cancer	2.82e-05	0.000482	CbGpPWpGaD
Raltegravir—Decreased appetite—Doxorubicin—lung cancer	2.81e-05	0.000185	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EGFR—lung cancer	2.81e-05	0.000481	CbGpPWpGaD
Raltegravir—Gastrointestinal disorder—Doxorubicin—lung cancer	2.79e-05	0.000184	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—lung cancer	2.78e-05	0.000184	CcSEcCtD
Raltegravir—Pain—Doxorubicin—lung cancer	2.76e-05	0.000182	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—lung cancer	2.76e-05	0.000182	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTT1—lung cancer	2.75e-05	0.000471	CbGpPWpGaD
Raltegravir—Hypersensitivity—Methotrexate—lung cancer	2.75e-05	0.000181	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP2A6—lung cancer	2.72e-05	0.000465	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GCLC—lung cancer	2.72e-05	0.000465	CbGpPWpGaD
Raltegravir—Asthenia—Methotrexate—lung cancer	2.68e-05	0.000177	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—lung cancer	2.66e-05	0.000176	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KRAS—lung cancer	2.65e-05	0.000454	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Doxorubicin—lung cancer	2.64e-05	0.000174	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—lung cancer	2.64e-05	0.000174	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ENO1—lung cancer	2.58e-05	0.000441	CbGpPWpGaD
Raltegravir—Urticaria—Doxorubicin—lung cancer	2.57e-05	0.000169	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—lung cancer	2.55e-05	0.000168	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—lung cancer	2.55e-05	0.000168	CcSEcCtD
Raltegravir—Diarrhoea—Methotrexate—lung cancer	2.55e-05	0.000168	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—lung cancer	2.47e-05	0.000163	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—lung cancer	2.44e-05	0.000417	CbGpPWpGaD
Raltegravir—Hypersensitivity—Doxorubicin—lung cancer	2.38e-05	0.000157	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—lung cancer	2.37e-05	0.000156	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TP53—lung cancer	2.36e-05	0.000403	CbGpPWpGaD
Raltegravir—Rash—Methotrexate—lung cancer	2.35e-05	0.000155	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—lung cancer	2.35e-05	0.000155	CcSEcCtD
Raltegravir—Headache—Methotrexate—lung cancer	2.34e-05	0.000154	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—lung cancer	2.32e-05	0.000153	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP2E1—lung cancer	2.31e-05	0.000396	CbGpPWpGaD
Raltegravir—Pruritus—Doxorubicin—lung cancer	2.28e-05	0.000151	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NQO1—lung cancer	2.28e-05	0.000391	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HRAS—lung cancer	2.25e-05	0.000386	CbGpPWpGaD
Raltegravir—Nausea—Methotrexate—lung cancer	2.22e-05	0.000146	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—lung cancer	2.21e-05	0.000146	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL6—lung cancer	2.16e-05	0.000369	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—lung cancer	2.14e-05	0.000141	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—STK11—lung cancer	2.06e-05	0.000353	CbGpPWpGaD
Raltegravir—Vomiting—Doxorubicin—lung cancer	2.05e-05	0.000135	CcSEcCtD
Raltegravir—Rash—Doxorubicin—lung cancer	2.04e-05	0.000134	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—lung cancer	2.03e-05	0.000134	CcSEcCtD
Raltegravir—Headache—Doxorubicin—lung cancer	2.02e-05	0.000133	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—AKT1—lung cancer	1.99e-05	0.000341	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—lung cancer	1.92e-05	0.000127	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTP1—lung cancer	1.9e-05	0.000326	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CAT—lung cancer	1.85e-05	0.000317	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCB1—lung cancer	1.8e-05	0.000309	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TYMS—lung cancer	1.77e-05	0.000303	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTM1—lung cancer	1.75e-05	0.0003	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP1A1—lung cancer	1.66e-05	0.000284	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ERCC2—lung cancer	1.65e-05	0.000282	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOA1—lung cancer	1.42e-05	0.000244	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—lung cancer	1.3e-05	0.000223	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—POMC—lung cancer	1.24e-05	0.000212	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CREBBP—lung cancer	1.21e-05	0.000206	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CD—lung cancer	1.14e-05	0.000196	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALB—lung cancer	1.13e-05	0.000193	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CB—lung cancer	9.96e-06	0.000171	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—lung cancer	9.87e-06	0.000169	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—lung cancer	8.61e-06	0.000147	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—EP300—lung cancer	8.21e-06	0.000141	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—lung cancer	6.07e-06	0.000104	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—lung cancer	4.96e-06	8.49e-05	CbGpPWpGaD
